NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $43.79 +3.79 (+9.48%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$43.80 +0.01 (+0.02%) As of 10/23/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Genmab A/S Stock (NASDAQ:GMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$39.63▼$44.3450-Day Range$32.23▼$43.7952-Week Range$23.62▼$44.34Volume13.00 million shsAverage Volume4.48 million shsMarket Capitalization$27.33 billionP/E Ratio34.48Dividend YieldN/APrice Target$43.39Consensus RatingModerate Buy Company Overview Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins. Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen. The company also maintains a pipeline of investigational antibody therapeutics and technology-based collaborations. Founded in 1999, Genmab operates internationally through research and development activities and partnerships with pharmaceutical companies. Its operations and collaborations extend across North America, Europe and other global markets. The company is led by Chief Executive Officer Anthony Mancini.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreGMAB MarketRank™: 3.055555555555 of 5 starsGenmab A/S scored higher than 61% of companies evaluated by MarketBeat, and ranked 314th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingModerate Buy Consensus RatingGenmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Genmab A/S is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGenmab A/S has only been the subject of 4 research reports in the past 90 days.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth30.33% Earnings GrowthEarnings for Genmab A/S are expected to grow by 30.33% in the coming year, from $1.22 to $1.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 34.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 34.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.89.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.99% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 23.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.62 News SentimentGenmab A/S has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Genmab A/S this week, compared to 6 articles on an average week.Search InterestOnly 9 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows7 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by Institutions7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Stock News HeadlinesGenmab A/S Announces Rinatabart Sesutecan Demonstrates Statistically Significant Improvement In Progression-Free Survival And Overall Survival In Patients With Platinum ...October 24 at 7:32 AM | marketscreener.comMGenmab's Rina-S Meets Phase 3 Primary Endpoint in Ovarian Cancer TrialOctober 23 at 6:39 PM | finance.yahoo.comElon gets it. Do you?Moderna shares surged almost 200% in a single day after a successful phase 3 trial for its cancer drug, while Merck added $43 billion in market cap on the same news. Porter & Co. has already guided readers to gains of 237% on uniQure, 206% on Sagimet Biosciences, and 156% on TG Therapeutics - six of the firm's top ten performing positions are in biotech.October 24 at 1:00 AM | Porter & Company (Ad)Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsOctober 23 at 1:37 PM | finance.yahoo.comGenmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum ...October 23 at 1:37 PM | markets.businessinsider.comGenmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerOctober 23 at 11:55 AM | globenewswire.comQ4 Earnings Forecast for Genmab A/S Issued By HC WainwrightOctober 22 at 1:13 AM | americanbankingnews.comBarclays Sticks to Their Buy Rating for Genmab A/S (0MGB)October 15, 2026 | theglobeandmail.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $30.80 on January 1st, 2026. Since then, GMAB stock has increased by 42.2% and is now trading at $43.79. How were Genmab A/S's earnings last quarter? Genmab A/S Sponsored ADR (NASDAQ:GMAB) announced its earnings results on Thursday, August, 6th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.37 by $0.17. The firm earned $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a trailing twelve-month return on equity of 14.89%. Read the conference call transcript. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional investors include Perpetual Ltd (0.12%), Legacy Wealth Asset Management LLC (0.02%), Terra Nova Asset Management LLC (0.01%) and Quadrant Capital Group LLC. How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Marvell Technology (MRVL), PayPal (PYPL), Palantir Technologies (PLTR), Fortinet (FTNT) and Salesforce (CRM). Company Calendar Last Earnings8/06/2026Today10/24/2026Study result10/28/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GMAB's financial health is in the Green zone, according to TradeSmith. GMAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees3,029Year Founded1999Price Target and Rating Average Price Target for Genmab A/S$43.39 High Price Target$54.00 Low Price Target$32.00 Potential Upside/Downside-0.9%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$1.27 Trailing P/E Ratio34.48 Forward P/E Ratio35.89 P/E Growth1.84Net Income$963 million Net Margins19.08% Pretax Margin21.93% Return on Equity14.89% Return on Assets7.73% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$4.13 billion Price / Sales6.62 Cash Flow$1.76 per share Price / Cash Flow24.85 Book Value$9.10 per share Price / Book4.81Miscellaneous Outstanding Shares624,059,000Free Float614,448,000Market Cap$27.33 billion OptionableOptionable Beta0.81 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:GMAB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredElon gets it. Do you?Moderna shares surged almost 200% in a single day after a successful phase 3 trial for its cancer drug, while ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
